Solara Active Pharma Sciences Ltd
NSE:SOLARA
Intrinsic Value
Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. [ Read More ]
The intrinsic value of one
SOLARA
stock under the Base Case scenario is
368.71
INR.
Compared to the current market price of 429.95 INR,
Solara Active Pharma Sciences Ltd
is
Overvalued by 14%.
Solara Active Pharma Sciences Ltd's market capitalization is 20.6B INR.
SOLARA stock price is 429.95 INR.
SOLARA stock (368.71 INR) is 14% less than its price (429.95 INR).
SOLARA stock (211.54 INR) is 51% less than its price (429.95 INR). Open DCF Valuation
SOLARA stock price (429.95 INR) is 18% less than its Relative Value (525.88 INR). Open Relative Valuation
SOLARA has downside potential of 21% compared to the average analyst price target.
Open Wall St Estimates
SOLARA's Revenue has dropped by 11% over the past 12 months.
SOLARA's Revenue has been falling by 7% per year for the last 3 years.
SOLARA has negative Operating Income for the last twelve months.
SOLARA's long-term assets (24B INR) exceed its long-term liabilties (14B INR).
SOLARA has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
SOLARA's ROE (Return on Equity) has significantly decreased in the last 3 years from 17% to -47%.
SOLARA's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 14% to -10%.
SOLARA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -10%.
SOLARA has negative Net Income for the last twelve months.
SOLARA's short-term liabilties (12B INR) exceed its short-term assets (8B INR).
SOLARA has positive Gross Profit for the last twelve months.
SOLARA's ROE (Return on Equity) for the past 12 months is negative and is equal to -47%.
SOLARA has negative three-year average ROE (Return on Equity): -4%. The company is not efficient at transforming stockholders' equity into net income.
SOLARA's Altman Z-Score is very low and is equal to 1.32.
SOLARA has positive Free Cash Flow for the last twelve months.
SOLARA has positive Net Debt. This means that the company has more debt (1B INR) than cash and short-term investments (160m INR).
SOLARA's D/E (Debt to Equity) is very low and is equal to 0.13.
SOLARA doesn't generate enough operating income (-2B INR) to safely cover interest payments on its debt (1B INR).
Valuation Backtest
Solara Active Pharma Sciences Ltd
Run backtest to discover the historical profit from buying and selling
SOLARA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Solara Active Pharma Sciences Ltd
Balance Sheet Decomposition
Solara Active Pharma Sciences Ltd
| Current Assets | 8B |
| Cash & Short-Term Investments | 160.2m |
| Receivables | 3.5B |
| Other Current Assets | 4.4B |
| Non-Current Assets | 15.5B |
| Long-Term Investments | 40.9m |
| PP&E | 11.1B |
| Intangibles | 4.1B |
| Other Non-Current Assets | 242.5m |
| Current Liabilities | 12.4B |
| Accounts Payable | 3.1B |
| Accrued Liabilities | 19.7m |
| Other Current Liabilities | 9.3B |
| Non-Current Liabilities | 1.7B |
| Long-Term Debt | 1.2B |
| Other Non-Current Liabilities | 567.6m |
Earnings Waterfall
Solara Active Pharma Sciences Ltd
|
Revenue
|
12.9B
INR
|
|
Cost of Revenue
|
-8.1B
INR
|
|
Gross Profit
|
4.8B
INR
|
|
Operating Expenses
|
-6.8B
INR
|
|
Operating Income
|
-2B
INR
|
|
Other Expenses
|
-3.7B
INR
|
|
Net Income
|
-5.7B
INR
|
Free Cash Flow Analysis
Solara Active Pharma Sciences Ltd
| INR | |
| Free Cash Flow | INR |
SOLARA Profitability Score
Profitability Due Diligence
Solara Active Pharma Sciences Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Solara Active Pharma Sciences Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
SOLARA Solvency Score
Solvency Due Diligence
Solara Active Pharma Sciences Ltd's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Solara Active Pharma Sciences Ltd's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SOLARA Price Targets Summary
Solara Active Pharma Sciences Ltd
According to Wall Street analysts, the average 1-year price target for
SOLARA
is 337.95 INR
with a low forecast of 296.94 INR and a high forecast of 387.09 INR.
Shareholder Return
SOLARA Price
Solara Active Pharma Sciences Ltd
| Average Annual Return | 27.02% |
| Standard Deviation of Annual Returns | 106.61% |
| Max Drawdown | -84% |
| Market Capitalization | 20.6B INR |
| Shares Outstanding | 47 995 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Solara Active Pharma Sciences Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2018-06-27. The firm is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). The company provides services, such as synthetic development, analytical development, process engineering, and regulatory services.
Contact
IPO
Employees
Officers
The intrinsic value of one
SOLARA
stock under the Base Case scenario is
368.71
INR.
Compared to the current market price of 429.95 INR,
Solara Active Pharma Sciences Ltd
is
Overvalued by 14%.
You don't have any saved screeners yet
